ArticleActa neuropathologica communications2026
Single cell protein profiling of focal cortical dysplasia in a patient requiring multiple resections.
Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Epilepsy affects millions worldwide with many failing to respond to standard treatments. Drug-refractory epilepsy requiring surgical intervention often presents due to developmental aberrations, such as focal cortical dysplasia (FCD). In FCD type II, somatic mutations in the mTOR pathway allow excessive activation of the mTOR kinase, causing unregulated cell growth and differentiation. Ex vivo studies of resected brain tissues offer a direct window into epileptogenic brain and disease pathophysiology. Recent studies implicate abnormal cell fate specification in FCD, but it is unclear if mutant cells are directly epileptogenic and/or whether they impact neighboring cells. Using a custom 43-antibody mass cytometry panel, we broadly assessed cell lineage and functional state across multiple sequential resections from a female child with FCD harboring a mosaic gain-of-function AKT3 mutation. Our approach used unsupervised machine learning tools to define protein-level features of dysplasia-associated cells and revealed cell populations associated with clinical outcomes. While AKT3 mutational burden did not correlate with clinical outcomes, protein profiling identified a distinct population of CUX1-high cells correlating with seizure control. Furthermore, we identified a similar cell population across multiple additional cortical malformation cases. This work demonstrates the advantage of deep single-cell protein profiling of surgically resected epilepsy tissue and provides insight on disease mechanisms that can be overlooked in traditional genetic or transcriptional studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.